Analysis of maxillary asymmetry before and after treatment of functional posterior cross-bite: a retrospective study using 3D imaging system and deviation analysis

BACKGROUND

Previous evidence would suggest that subjects affected by functional posterior cross-bite (FPXB) present an asymmetric morphology of the maxilla. However, no evidence is available concerning the morphology (symmetry/asymmetry) of the maxilla after treatment of FPXB. This study aimed to investigate the volumetric and morphological changes of the palate in FPXB subjects treated with maxillary expansion and to compare these data with an untreated control group. The study sample included 20 FPXB subjects (mean age 8.1 ± 0.9 years) who underwent maxillary expansion (MEG group) and 21 FPXB subjects (mean age 7.7 ± 1.2 years) as controls (CG group). Digital models were recorded at T0 (first observation) and T1 (12-18 months after first observation) and analyzed to assess palatal volume and symmetry. Deviation analysis and percentage matching calculation were also performed between original and mirrored palatal models for each patient. All data were statistically analyzed for intra-timing, inter-timing and inter-groups assessments.

RESULTS

At T0, the cross-bite side (CBS) was significantly smaller than non-cross-bite side (non-CBS) in both groups (p < 0.05). At T1, the CBS/non-CBS difference reduced significantly in the MEG group (p < 0.05) while slightly worsened in the CG, however without statistical significance (p > 0.05). The matching percentage of the palatal models improved significantly at T1 in the MEG group (T0 = 74.02% ± 9.8; T1 = 89.95% ± 7.12) (p < 0.05) while no significant differences were recorded in the CG (T0 = 76.36 ± 8.64; 72.18% ± 9.65) (p > 0.05).

LIMITATIONS

The small sample size and the retrospective design of the study represent two limitations that should be overcome with further clinical trials.

CONCLUSIONS

Subjects with FPXB present an asymmetric development of the maxillary vault that improves after reestablishment of normal occlusion following maxillary expansion.

Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. A phase II study. North-Eastern Italian Oncology Group (GOCCNE)

OBJECTIVE

The effectiveness of a chemotherapy regimen including cisplatin, epirubicin, and estramustine phosphate was evaluated in a series of young patients with prostate cancer.

METHODS

28 patients with a histological diagnosis of prostatic carcinoma, age < 70 years, performance status (PS) < 2, hormone-refractory status, life expectancy > 3 months, were treated with cisplatin 60 mg/m2 i.v. and epirubicin 60 mg/m2 i.v. every 3 weeks for six cycles. Estramustine phosphate was administered at a dosage of 10 mg/kg p.o. in two divided daily doses during intravenous chemotherapy and until progression thereafter. The response was assessed after three cycles of chemotherapy, evaluating again the disease parameters. In case of partial remission or stable disease, treatment was continued for three additional cycles. The median age was 61.5 years, the median PS was 70.

RESULTS

11 partial remissions, 13 patients with stable disease, and 4 progressions were noted. The response rate (only partial remissions) was 39% (95% confidence limits 21-57%). The median duration of the partial remissions) was 11 (range 6-25) months. A subjective improvement of symptoms was observed in 17 of 19 patients. Toxicity was acceptable with no deaths. The median overall survival was 15 months.

CONCLUSIONS

The combination studied had activity in young prostate cancer patients, and our results suggest that this subset of patients needs specifically devised chemotherapy regimens.